Anti-IgE [EPC]

87093 reported adverse events

Drugs of this class: OMALIZUMAB OMALIZUMAB-IGEC

These side effects are most commonly reported by patients taking drugs of the Anti-IgE [EPC] class:

# Side effect Count
0 ASTHMA 12371
1 URTICARIA 11750
2 NO ADVERSE EVENT 11200
3 OFF LABEL USE 11100
4 DYSPNOEA 10558
5 DRUG INEFFECTIVE 8627
6 COUGH 7198
7 PRURITUS 6583
8 FATIGUE 6267
9 MALAISE 5801
See all common reactions for Anti-IgE [EPC]

Drugs of the Anti-IgE [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CHRONIC SPONTANEOUS URTICARIA 742 0.6397
1 FORCED EXPIRATORY VOLUME DECREASED 1628 0.5740
2 IDIOPATHIC URTICARIA 603 0.5604
3 BRONCHOPULMONARY ASPERGILLOSIS ALLERGIC 392 0.4229
4 BLOOD IMMUNOGLOBULIN E INCREASED 827 0.3412
5 MAST CELL ACTIVATION SYNDROME 372 0.2650
6 NASAL OEDEMA 402 0.2223
7 ASTHMATIC CRISIS 778 0.2128
8 SPUTUM DISCOLOURED 1657 0.1745
9 OBSTRUCTIVE AIRWAYS DISORDER 1882 0.1690
See all enriched reactions for Anti-IgE [EPC]